Laktatazidose und mikrovesikuläre hepatische Steatose als schwerwiegende Komplikation einer antiretroviralen Therapie bei HIV-Patienten - Zweiter Kommentar

Literatur

• 1 Nunez M, Soriano V. Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients.  J Hepatol. 2005;  42 290-292
• 2 Spengler U, Lichterfeld M, Rockstroh J K. Antiretroviral drug toxicity - a challenge for the hepatologist?.  J Hepatol. 2002;  36 283-294
• 3 Lee W M. Drug-induced hepatotoxicity.  N Engl J Med. 2003;  349 474-485
• 4 McKenzie R, Fried M W, Sallie R, Conjeevaram H, Bisceglie A M, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka J L, Straus S E, Hoofnagle J H. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis.  B N engl J Med. 1995;  333 1099-1105
• 5 ter Hofstede H J, de Marie S, Foudraine N A, Danner S A, Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases.  Int J STD AIDS. 2000;  11 611-616
• 6 Clark S J, Creighton S, Portmann B, Taylor C, Wendon J A, Cramp M E. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases.  J Hepatol. 2002;  36 295-301